Pelengaris, Stella, Abouna, Sylvie, Cheung, Linda, Ifandi, Vasiliki, Zervou, Sevasti I. and Khan, Michael. (2004) Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis. BMC Biology, Vol.2 (No.26). ISSN 1741-7007

Preview

PDF WRAP_Pelengaris_Brief_inactivation.pdf - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Download (5Mb)

Abstract

Background Tumour regression observed in many conditional mouse models following oncogene inactivation provides the impetus to develop, and a platform to preclinically evaluate, novel therapeutics to inactivate specific oncogenes. Inactivating single oncogenes, such as c-Myc, can reverse even advanced tumours. Intriguingly, transient c-Myc inactivation proved sufficient for sustained osteosarcoma regression; the resulting osteocyte differentiation potentially explaining loss of c-Myc's oncogenic properties. But would this apply to other tumours? Results We show that brief inactivation of c-Myc does not sustain tumour regression in two distinct tissue types; tumour cells in pancreatic islets and skin epidermis continue to avoid apoptosis after c-Myc reactivation, by virtue of Bcl-xL over-expression or a favourable microenvironment, respectively. Moreover, tumours progress despite reacquiring a differentiated phenotype and partial loss of vasculature during c-Myc inactivation. Interestingly, reactivating c-Myc in β-cell tumours appears to result not only in further growth of the tumour, but also re-expansion of the accompanying angiogenesis and more pronounced β-cell invasion (adenocarcinoma). Conclusions Given that transient c-Myc inactivation could under some circumstances produce sustained tumour regression, the possible application of this potentially less toxic strategy in treating other tumours has been suggested. We show that brief inactivation of c-Myc fails to sustain tumour regression in two distinct models of tumourigenesis: pancreatic islets and skin epidermis. These findings challenge the potential for cancer therapies aimed at transient oncogene inactivation, at least under those circumstances where tumour cell differentiation and alteration of epigenetic context fail to reinstate apoptosis. Together, these results suggest that treatment schedules will need to be informed by knowledge of the molecular basis and environmental context of any given cancer.

Item Type:	Journal Article
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions:	Faculty of Science > Life Sciences (2010- ) > Biological Sciences ( -2010)
Library of Congress Subject Headings (LCSH):	Tumour regression, Tumors -- Growth, Oncogenes
Journal or Publication Title:	BMC Biology
Publisher:	BioMed Central Ltd.
ISSN:	1741-7007
Date:	21 December 2004
Volume:	Vol.2
Number:	No.26
Identification Number:	10.1186/1741-7007-2-26
Status:	Peer Reviewed
Access rights to Published version:	Open Access
Funder:	Biotechnology and Biological Sciences Research Council (Great Britain) (BBSRC), Association for International Cancer Research (AICR)
References:	1. Giuriato S, Rabin K, Fan AC, Shachaf CM, Felsher DW: Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer. Semin Cancer Biol 2004, 14:3-11. 2. Felsher DW: Cancer revoked: oncogenes as therapeutic targets. Nat Rev Cancer 2003, 3:375-380. 3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792. 4. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031-1037. 5. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti- Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002, 346:645-652. 6. Felsher DW, Bishop JM: Reversible tumourigenesis by MYC in hematopoietic lineages. Mol Cell 1999, 4:199-207. 7. Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, Shen Q, O'Hagan R, Pantginis J, Zhou H, Horner JW 2nd, Cordon-Cardo C, Yancopoulos GD, DePinho RA: Essential role for oncogenic Ras in tumour maintenance. Nature 1999, 400:468-472. 8. Pelengaris S, Littlewood T, Khan M, Elia G, Evan G: Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 1999, 3:565-577. 9. Pelengaris S, Khan M, Evan GI: Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 2002, 109:321-334. 10. Huettner CS, Zhang P, Van Etten RA, Tenen DG: Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 2000, 24:57-60. 11. D'Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE, Cox JD, Ha SI, Belka GK, Golant A, Cardiff RD, Chodosh LA: c- MYC induces mammary tumourigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 2001, 7:235-239. 12. Fisher GH, Wellen SL, Klimstra D, Lenczowski JM, Tichelaar JW, Lizak MJ, Whitsett JA, Koretsky A, Varmus HE: Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumour suppressor genes. Genes Dev 2001, 15:3249-3262. 13. Wang R, Ferrell LD, Faouzi S, Maher JJ, Bishop JM: Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol 2001, 153:1023-1034. 14. Moody SE, Sarkisian CJ, Hahn KT, Gunther EJ, Pickup S, Dugan KD, Innocent N, Cardiff RD, Schnall MD, Chodosh LA: Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2002, 2:451-461. 15. Karlsson A, Giuriato S, Tang F, Fung-Weier J, Levan G, Felsher DW: Genomically complex lymphomas undergo sustained tumour regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood 2003, 101:2797-2803. 16. Gunther EJ, Moody SE, Belka GK, Hahn KT, Innocent N, Dugan KD, Cardiff RD, Chodosh LA: Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumourigenesis. Genes Dev 2003, 17:488-501. 17. Pao W, Klimstra DS, Fisher GH, Varmus HE: Use of avian retroviral vectors to introduce transcriptional regulators into mammalian cells for analyses of tumour maintenance. Proc Natl Acad Sci USA 2003, 100:8764-8769. 18. Marinkovic D, Marinkovic T, Mahr B, Hess J, Wirth T: Reversible lymphomagenesis in conditionally c-MYC expressing mice. Int J Cancer 2004, 110:336-342. 19. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM, Felsher DW: Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002, 297:102-104. 20. Pelengaris S, Khan M, Evan GI: c-Myc: more than just a matter of life and death. Nature- reviews cancer 2002, 2:764-776. 21. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, Yang Q, Bishop JM, Contag CH, Felsher DW: MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004, 431:1112-7. 22. Naik P, Karrim J, Hanahan D: The rise and fall of apoptosis during multistage tumourigenesis: down-modulation contributes to tumour progression from angiogenic progenitors. Genes Dev 1996, 10:2105-2116. 23. Roberts RB, Arteaga CL, Threadgill DW: Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies. Cancer Cell 2004, 5:115-120. 24. Felsher DW, Bradon N: Pharmacological inactivation of MYC for the treatment of cancer. Drug News Perspect 2003, 16:370-374. 25. Noble ME, Endicott JA, Johnson LN: Protein kinase inhibitors: insights into drug design from structure. Science 2004, 303:1800-1805. 26. Dor Y, Brown J, Martinez OI, Melton DA: Adult pancreatic betacells are formed by self-duplication rather than stem-cell differentiation. Nature 2004, 429:41-46. 27. Bachoo RM, Kim RS, Ligon KL, Maher EA, Brennan C, Billings N, Chan S, Li C, Rowitch DH, Wong WH, DePinho RA: Molecular diversity of astrocytes with implications for neurological disorders. Proc Natl Acad Sci U S A 2004, 101:8384-8389. 28. Flores I, Murphy DJ, Swigart LB, Knies U, Evan GI: Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia. Oncogene 2001 in press. 29. Pavelic K, Hrascan R, Kapitanovic S, Karapandza N, Vranes Z, Belicza M, Kruslin B, Cabrijan T: Multiple genetic alterations in malignant metastatic insulinomas. J Pathol 1995, 177:395-400. 30. Pavelic K, Hrascan R, Kapitanovic S, Vranes Z, Cabrijan T, Spaventi S, Korsic M, Krizanac S, Li YQ, Stambrook P, Gluckman JL, Pavelic ZP: Molecular genetics of malignant insulinoma. Anticancer Res 1996, 16:1707-1717. 31. Garte SJ: The c-myc oncogene in tumor progression. Crit Rev Oncog 2003, 4:435-449. 32. Pelisson I, Soler C, Pechoux C, Chignol MC, Viac J, Euvrard S, Chardonnet Y: c-myc and c-Ha-ras cellular oncogenes and human papillomaviruses in benign and malignant cutaneous lesions. J Dermatol Sci 1992, 3:56-67. 33. Littlewood T, Hancock D, Danielian P, Parker M, Evan G: A modified estrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acid Res 1995, 23:1686-1690.
URI:	http://wrap.warwick.ac.uk/id/eprint/574

Request changes to a record

Actions (login required)

View Item